Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vicept Therapeutics has reported positive results from a Phase II clinical trial evaluating V-101 cream, a topical cream for the treatment of type I Rosacea (Erythematotelangiectatic Rosacea).
Subscribe to our email newsletter
The results showed improvement in the primary end point, which was defined as a reduction in facial erythema, over an eight hour period in patients with erythematotelangiectatic rosacea (ETR), compared to placebo
In addition, V-101 demonstrated a safety profile similar to placebo cream, without any evidence of ‘rebound’ or tachyphylaxis.
Vicept said the prospectively randomised, multi-centred, double-blinded, placebo-controlled, Phase II clinical trial was designed to assess the dose-response relationship of four concentrations of V-101 cream versus placebo for the treatment of the erythema associated with rosacea.
The study enrolled a total of 183 patients with moderate to severe erythema at seven investigational centers across the US.
Patients were divided among five groups and self-administered one of four concentrations of V-101 cream or placebo cream, once daily for 28 days.